What the trials showed
In Eli Lilly’s Phase 2 obesity study, retatrutide produced some of the largest average weight reductions reported for this drug class — up to roughly 24% of body weight at the highest dose over about 48 weeks. Results were dose-dependent: higher studied doses produced more weight loss on average.
Typical timeline
As with other incretin drugs, appetite reduction often begins within the first weeks, while meaningful weight change accrues over months as the dose is escalated. Trial participants continued to lose weight through the full study period at the higher doses.
See how it stacks up against approved options in our retatrutide vs tirzepatide and retatrutide vs Ozempic comparisons.
Important: retatrutide is not FDA-approved
Retatrutide is still in Phase 3 trials and cannot be legally prescribed or sold as a finished drug in the U.S. If you want a clinician-supervised, FDA-approved GLP-1 for weight loss today, a licensed telehealth provider can assess whether semaglutide or tirzepatide is right for you.
See FDA-approved options →Find a retatrutide trialFrequently asked questions
How much weight did people lose on retatrutide?
How long does retatrutide take to work?
Dose with confidence — free tips by email
Practical dosing guides, reconstitution tips, and ways to save on your meds — about once a week, no fluff.